StageMerger | Merged
NURX aims to reduce the barriers to getting medications such as birth control for everyone, regardless of where they live. NURX prescribes and delivers medication without users ever having to set foot in a doctor's office. The company is starting by prescribing and delivering birth control and emergency contraceptives, and next plans to expand to offer HIV prevention medications Truvada and PReP. The company was founded in 2015 and is based in San Francisco, California. On February 9th, 2022, NURX merged with Thirty Madison.
Missing: NURX's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: NURX's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing NURX
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned NURX in 7 CB Insights research briefs, most recently on Nov 1, 2021.
Expert Collections containing NURX
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
NURX is included in 8 Expert Collections, including E-Commerce.
Women's Health & Wellness
Startups focused on providing products and services catering to women's health and wellbeing.
Pharma Supply Chain
Digital Health 150
2019's cohort of the most promising digital health startups transforming the healthcare industry
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.
Latest NURX News
Feb 17, 2023
The global HPV testing and Pap test market was valued at USD 3.30 billion in 2021, growing at a CAGR of 6.17% during the forecast period from 2022 to 2027 to reach USD 4.72 billion by 2027. The HPV testing and Pap test market is anticipated to witness prosperity owing to factors such rising prevalence of cervical cancer globally and the increasing number of screening programs. An increase in awareness towards HPV and Pap tests is another factor that will result in appreciable revenue growth in the HPV testing and pap test market during the forecast period (2022-2027). HPV Testing And PAP Test Market Dynamics: One of the major factors which are driving the HPV testing and pap test market is the rising prevalence of cervical cancer. Cervical cancer is a type of cancer that occurs in the cells of the cervix which is the lower part of the uterus that connects to the vagina. The increase in the rate of cervical cases has created an awareness for prior screening and testing which has led to a growth in the HPV testing and pap test market. Thus, the increasing prevalence of cervical cancer among women of reproductive age is increasing the demand for HPV testing and pap test, which is anticipated to boost the market's growth over the forecast period from 2022-2027. Moreover, increasing initiatives by government bodies to create awareness for cervical cancer has further increased the market for HPV screening thereby fueling the market growth for HPV testing and pap test. For instance, the World Health Assembly in 2020 adopted the global strategy to accelerate the elimination of cervical cancer as a public health problem. The definition of elimination of cervical cancer has been set up as a country reaching the threshold of fewer than 4 cases of cervical cancer per 100,000 women per year. To reach this threshold by the end of the 21st century, WHO has set up a target to be reached by 2030 by screening 70% of women with a high-performance test by 35, and again by 45 years of age. Thus, driving the growth of the HPV testing and pap test market in the forecast period of 2022-2027. Furthermore, advancement in product development for the screening of HPV has led to lucrative growth opportunities in the HPV testing and pap test market growth. Companies like Qiagen are having technologically advanced tests that detect HPV DNA such as the Capture 2 test, which detects the presence of 13 high-risk HPV types in the cervical sample. Furthermore, the launch of the HPV vaccine against the virus to ensure the decline in cervical cancer is one of the restraining factors to the growth of the HPV testing and pap test market that will impact the market growth during the forecast period from 2022-2027. HPV Testing And PAP Test Market Segment Analysis: HPV testing and Pap test market by Test Type (Primary HPV Testing, Co-Testing, and Pap Test), by Application (Cervical Cancer, Vaginal Cancer, and Others), by Technology Type (Polymerase Chain Reaction, and Others), by End-User (Hospitals And Clinics, Diagnostic Laboratories, and Others), by Geography (North America, Europe, Asia-Pacific, and Rest of the World). Based on the application segment of the HPV testing and pap test market, cervical cancer accounted for the largest market share in the year 2021. This can be ascribed to the increase in cervical cancer screening tests lately. Cervical cancer screening is an essential part of a woman's routine healthcare. For women of age 30 years and above, an HPV test is recommended for detection. Almost 95% of cervical cancer causes the causative organisms estimated to be the HP virus. The screening helps identify precancerous lesions caused by HPV so they can be removed to prevent invasive cancers from developing. The data published by WHO in 2022 states that cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020. About 90% of the new cases and deaths worldwide in 2020 occurred in low- and middle-income countries. Therefore, the WHO in 2020 adopted the Global strategy towards eliminating cervical cancer as a public health problem and recommends a comprehensive approach to cervical cancer prevention and control. All these increases in cervical cancer numbers and subsequent awareness programs for the same correspond to the increased market share of the segment, thereby increasing the market growth for the HPV testing and pap test market. North America is expected to dominate the overall HPV Testing And PAP Test Market: Among all the regions, North America is expected to lead in revenue generation in the global HPV testing and pap test market. The highest growth in the region is registered due to the reasons such as rising cases of cervical cancer, numerous awareness initiatives, and high research and development activities in the arena which pay the way for the launch of advanced products in the region. As per CDC 2022 data, each year in the US, about 13,000 new cases of cervical cancer are diagnosed and about 4,000 women die of this cancer. Hispanic women have the highest rates of developing cervical cancer, and Black women have the highest rates of dying from cervical cancer. Therefore, such numbers indicate considerable market growth in this region. Therefore, with the rising cases of cervical cancer in the region, the government has adopted various awareness programs to decrease the incidence rate of the disease. A few of them are the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for breast and cervical cancer screening, the National Cervical Cancer Coalition, WHO, CDC, and the U.S. Preventive Services Task Force (USPSTF), for cervical cancer screening. This is one of the major factors expected to drive the North American market for HPV testing and Pap test during the forecast period. Apart from this, various research and development activities in the North American region for the HPV testing and pap test market are also key factors for the dominance in the market share. For instance, in 2019, researchers at Massachusetts General Hospital's Center for Systems Biology and Harvard Medical School, Boston presented a novel screening handheld device that uses Artificial Intelligence (AI) for HPV detection. The novel device detects the presence of HPV strains 16 and 18 in a turnaround time of 2 hours. Therefore, the above-mentioned factors are expected to bolster the growth of the HPV testing and pap test market in the North American region during the forecast period of 2022-2027. Key Takeaways from the HPV Testing And PAP Test Market Report Study Market size analysis for current HPV testing and pap test market size (2021), and market forecast for 5 years (2022-2027) The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the HPV testing and pap test market. Top key product developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years Key companies dominating the global HPV testing and pap test market. Various opportunities available for the other competitor in the HPV testing and pap test market space. What are the top performing segments in 2021? How these segments will perform in 2027. Which are the top-performing regions and countries in the current HPV testing and pap test market scenario? Which are the regions and countries where companies should have concentrated on opportunities for HPV testing and pap test market growth in the coming future? Target Audience who can be benefited from this HPV Testing And PAP Test Market Report Study HPV testing and pap test products providers Research organizations and consulting companies HPV testing and pap test -related organizations, associations, forums, and other alliances Government and corporate offices Distributors and Traders dealing in HPV testing and pap test Various distribution channels who want to know more about the HPV testing and pap test market and the latest product innovations in the HPV testing and pap test market. Frequently Asked Questions for HPV Testing and The PAP Test Market: 1. What are HPV testing and pap test? The HPV test looks for the virus (human papillomavirus) that can cause cell changes on the cervix causing cervical cancer. Whereas, the Pap test (or Pap smear) looks for precancers and cell changes on the cervix that might become cervical cancer if they are not treated appropriately. These tests include microscopic observation of specimens. 2. What is the market for global HPV testing and pap test? The global HPV testing and pap test market was valued at USD 3.30 billion in 2021, growing at a CAGR of 6.17% during the forecast period from 2022 to 2027 to reach USD 4.72 billion by 2027. 3. What are the drivers for the global HPV testing and pap test market? The HPV testing and pap test market is anticipated to witness prosperity owing to factors such rising prevalence of cervical cancer globally and the increasing number of screening programs. An increase in awareness towards HPV and Pap tests is another factor that will result in appreciable revenue growth in the HPV testing and pap test market during the forecast period (2022-2027). 4. Who are the key players operating in the global HPV testing and pap test market? Some of the key market players operating in the HPV testing and pap test market include Arbor Vita Corporation, Danaher Corporation (Cepheid), Seegene Inc., Becton, Dickinson and Company, TruScreen, Abbott Laboratories, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, OncoHealth Corporation, Takara Bio Inc., Promega Corporation, Quest Diagnostics, Femasys Inc., Mylab Discovery Solutions Pvt Ltd., Thermo Fisher Scientific Inc., bioMerieux SA, Nurx and others. 5. Which region has the highest share in the HPV testing and pap test market? Among all the regions, North America is expected to lead in revenue generation in the global HPV testing and pap test market. The highest growth in the region is registered due to the reasons such as rising cases of cervical cancer, numerous awareness initiatives, and high research and development activities in the arena which pay the way for the launch of advanced products in the region. A selection of companies mentioned in this report includes Arbor Vita Corporation Thermo Fisher Scientific Inc.
NURX Frequently Asked Questions (FAQ)
When was NURX founded?
NURX was founded in 2015.
Where is NURX's headquarters?
NURX's headquarters is located at 1125 Mission Street, San Francisco.
What is NURX's latest funding round?
NURX's latest funding round is Merger.
How much did NURX raise?
NURX raised a total of $115.92M.
Who are the investors of NURX?
Investors of NURX include Thirty Madison, Union Square Ventures, Kleiner Perkins Caufield & Byers, Comcast Ventures, Trustbridge Partners and 10 more.
Who are NURX's competitors?
Competitors of NURX include Twentyeight Health, Dadi, Ro, Wisp, Favor and 9 more.
Compare NURX to Competitors
Favor provides an online birth control prescription and delivery service to simplify access to birth control. It delivers birth control, emergency contraception, and complimentary gifts while offering a personalized and connected healthcare experience. It ensures accessibility and personal freedom while empowering women to take charge of their health and bodies. It was formerly known as The Pill Club. It was founded in 2014 and is based in San Mateo, California.
Ro is a patient-driven telehealth company that puts patients in control of their health. The company builds technology to make healthcare accessible, affordable, and enjoyable. Ro powers three digital health clinics: Roman for men’s health, Rory for women’s health, and Zero for fighting smoking cessation. It also operates Ro Pharmacy, a simple and affordable online pharmacy where every generic medication is $5 per month. Ro’s nationwide network of physicians and pharmacies provides a personalized, end-to-end healthcare experience from online treatment to the delivery of medication and ongoing care. The company was founded in 2017 and is based in New York, New York.
Simple Health (fka Simple Contacts) allows users to fill out medical history and personal preferences so doctors can prescribe a birth control brand that will be safe and effective.
ASYSTEM creates betterment products to help men look, feel, and perform at their best. Spanning supplements, vitamins, and personal care, its products combine science with nature. The company was founded in 2018 and is based in Venice, California.
Numan offers an online platform that aims to promote accessible medical remedies for erectile dysfunction. The company seeks to build a brand around health issues affecting men's self-esteem and the lifestyle choices they make that might affect their condition.
Pandia Health provides a one-stop shop for recurring medications, starting with birth control. Pandia Health offers free and discreet delivery of the pill, patch, or ring as well as emergency contraceptives.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.